MedTrace Logo

Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia

NCT04235634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2022-03-15

No results posted yet for this study

Summary

Minimal invasive intra-arterial prostaglandin therapy is currently being offered as an established and safe treatment approach for Non-occlusive mesenteric ischemia (NOMI). So far, there are no data that prospective evaluate clinical response parameters of this method and corresponding criteria for response.

The investigators are therefore planning a prospective observational study on NOMI patients with the aim to collect

1. routine clinical data,
2. data from advanced angigraphic imaging and
3. data from blood biomarkers of intestinal ischemia before/at implementation of intra-arterial vasodilatory therapy.

From these three data packages, the investigators hope to subsequentially derive criteria to better predict response to therapy.

Conditions

  • Non-Occlusive Mesenteric Ischaemia (NOMI)

Interventions

DRUG

Prostavasin

Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Markus Busch, MD · Clinic for gastroenterology and hepatology

  • Klaus Stahl, MD · Clinic for nephrology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-12-31
Completion
2022-02-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04235634 on ClinicalTrials.gov